GB2577420B - Glycopeptide derivative compounds and uses thereof - Google Patents

Glycopeptide derivative compounds and uses thereof Download PDF

Info

Publication number
GB2577420B
GB2577420B GB1917677.5A GB201917677A GB2577420B GB 2577420 B GB2577420 B GB 2577420B GB 201917677 A GB201917677 A GB 201917677A GB 2577420 B GB2577420 B GB 2577420B
Authority
GB
United Kingdom
Prior art keywords
derivative compounds
glycopeptide derivative
glycopeptide
compounds
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1917677.5A
Other languages
English (en)
Other versions
GB201917677D0 (en
GB2577420A (en
Inventor
Heckler Ryan
Konicek Donna
Plaunt Adam
Malinin Vladimir
Perkins Walter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insmed Inc
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of GB201917677D0 publication Critical patent/GB201917677D0/en
Publication of GB2577420A publication Critical patent/GB2577420A/en
Application granted granted Critical
Publication of GB2577420B publication Critical patent/GB2577420B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GB1917677.5A 2017-05-22 2018-05-22 Glycopeptide derivative compounds and uses thereof Active GB2577420B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762509378P 2017-05-22 2017-05-22
US201762518280P 2017-06-12 2017-06-12
US201762560413P 2017-09-19 2017-09-19
PCT/US2018/033953 WO2018217800A1 (en) 2017-05-22 2018-05-22 Glycopeptide derivative compounds and uses thereof

Publications (3)

Publication Number Publication Date
GB201917677D0 GB201917677D0 (en) 2020-01-15
GB2577420A GB2577420A (en) 2020-03-25
GB2577420B true GB2577420B (en) 2022-07-06

Family

ID=64395938

Family Applications (2)

Application Number Title Priority Date Filing Date
GB1917677.5A Active GB2577420B (en) 2017-05-22 2018-05-22 Glycopeptide derivative compounds and uses thereof
GB1917675.9A Active GB2577419B (en) 2017-05-22 2018-05-22 Lipo-glycopeptide cleavable derivatives and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1917675.9A Active GB2577419B (en) 2017-05-22 2018-05-22 Lipo-glycopeptide cleavable derivatives and uses thereof

Country Status (11)

Country Link
US (3) US11071769B2 (https=)
EP (2) EP3634464A4 (https=)
JP (2) JP7165146B2 (https=)
KR (2) KR102661786B1 (https=)
CN (2) CN110891590B (https=)
AU (2) AU2018271873B2 (https=)
BR (2) BR112019024549A2 (https=)
GB (2) GB2577420B (https=)
IL (2) IL270685B (https=)
NZ (1) NZ758836A (https=)
WO (2) WO2018217808A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801521B (zh) 2007-05-14 2015-06-17 纽约州立大学研究基金会 生物膜中细菌细胞内的生理学分散响应诱导
GB2577420B (en) * 2017-05-22 2022-07-06 Insmed Inc Glycopeptide derivative compounds and uses thereof
NL2023883B1 (en) * 2019-09-24 2021-04-26 Univ Leiden Antibiotic compounds
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023094994A1 (en) * 2021-11-24 2023-06-01 Cumberland Pharmaceuticals Inc Methods for the prevention or treatment of anthrax infection
CN121270649A (zh) * 2024-07-03 2026-01-06 烟台新药创制山东省实验室 一类万古霉素衍生物、其制备方法、药物组合物和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022590A1 (en) * 2000-06-22 2002-02-21 Leadbetter Michael R. Glycopeptide phosphonate derivatives
US7273845B2 (en) * 2002-11-12 2007-09-25 Enzon Pharmaceuticals, Inc. Polymeric prodrugs of vancomycin
WO2009042187A1 (en) * 2007-09-25 2009-04-02 Nektar Therapeutics Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
US20090104257A1 (en) * 2007-10-23 2009-04-23 Xingong Li Liposomal Vancomycin Formulations
WO2014085526A1 (en) * 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639433A (en) 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
PT86457B (pt) * 1986-12-30 1990-11-20 Smithkline Beecham Corp Processo para a preparacao de glicopeptidos glicosilados e de composicoes que os contem
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
PT101450B (pt) 1994-02-02 1999-11-30 Hovione Produtos Farmaceuticos Novo dispositivo para inalacao
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6077543A (en) 1996-12-31 2000-06-20 Inhale Therapeutic Systems Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
WO1999016420A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
CN1169520C (zh) 1997-09-29 2004-10-06 耐科塔医药公司 多孔微粒及其使用方法
US6518242B1 (en) * 1998-02-20 2003-02-11 Theravance, Inc. Derivatives of glycopeptide antibacterial agents
WO1999063929A2 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
UA73924C2 (en) 1998-10-09 2005-10-17 Nektar Therapeutics Device for delivering active agent formulation to lungs of human patient
DE69908819T2 (de) 1998-12-23 2004-05-06 Theravance, Inc., South San Francisco Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten
EP1181069B1 (en) 1999-05-28 2006-06-28 Nektar Therapeutics Apparatus and method for aerosolising a powder pharmaceutical composition
US6606992B1 (en) 1999-06-30 2003-08-19 Nektar Therapeutics Systems and methods for aerosolizing pharmaceutical formulations
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
AU2001238020A1 (en) 2000-02-04 2001-08-14 Advanced Medicine, Inc. Glycopeptide derivatives having antibiotic activity
MXPA02007739A (es) 2000-02-11 2002-10-11 Lilly Co Eli N-acilacion selectiva de analogos del glicopeptido a82846.
ES2525087T5 (es) 2000-05-10 2018-06-28 Novartis Ag Polvos basados en fosfolípidos para administración de fármacos
TWI312785B (en) * 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
US7521418B2 (en) * 2003-05-27 2009-04-21 Theravance, Inc. Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
US20070185015A1 (en) 2005-02-28 2007-08-09 Chiron Corporation and North China Pharmaceutical Corporation Semi-synthetic desmethyl-vancomycin-based glycopeptides with antibiotic activity
US7632918B2 (en) * 2005-02-28 2009-12-15 Novartis Vaccines And Diagnostics, Inc. Semi-synthetic glycopeptides with antibiotic activity
CN101959849A (zh) * 2007-12-26 2011-01-26 利德治疗公司 作为抗菌剂的新型半合成糖肽
US20100105607A1 (en) * 2008-10-24 2010-04-29 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
GB2465863A (en) * 2008-12-05 2010-06-09 Lead Therapeutics Inc Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections
US20120058198A1 (en) * 2009-03-26 2012-03-08 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
AU2010245097B2 (en) * 2009-04-28 2015-08-13 Melinta Therapeutics, Inc. Methods of treating bacterial infections using oritavancin
EP2709646A4 (en) * 2011-05-19 2015-05-13 Savara Inc DRY POWDER VANCOMYCIN COMPOSITIONS AND RELATED METHODS
US9572774B2 (en) * 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
EP2739289B1 (en) 2011-08-05 2020-05-06 The Scripps Research Institute Glycopeptide antibiotic analogs effective against vancomycin-resistant bacterial strains
MX369828B (es) * 2012-05-21 2019-11-22 Insmed Inc Sistemas para tratar infecciones pulmonares.
GB201402267D0 (en) * 2014-02-10 2014-03-26 Cambridge Entpr Ltd Antibacterial agents
CN105085636B (zh) * 2014-05-19 2020-05-01 中国医学科学院药物研究所 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用
CA2954653C (en) 2014-07-10 2023-01-24 The Scripps Research Institute N-(hydrophobe-substituted)vancosaminyl [.psi.[c(=nh)nh]tpg4]vancomycin and [.psi.[ch2nh]tpg4]vancomycin
CN107325159A (zh) 2016-04-29 2017-11-07 中国科学院上海药物研究所 一类万古霉素衍生物、其制备方法、药物组合物和用途
WO2018008197A1 (ja) 2016-07-07 2018-01-11 日東電工株式会社 反射層および蛍光体層付光半導体素子
AU2017348434B2 (en) 2016-10-31 2021-10-07 The Scripps Research Institute Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability
GB2577420B (en) 2017-05-22 2022-07-06 Insmed Inc Glycopeptide derivative compounds and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022590A1 (en) * 2000-06-22 2002-02-21 Leadbetter Michael R. Glycopeptide phosphonate derivatives
US7273845B2 (en) * 2002-11-12 2007-09-25 Enzon Pharmaceuticals, Inc. Polymeric prodrugs of vancomycin
WO2009042187A1 (en) * 2007-09-25 2009-04-02 Nektar Therapeutics Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
US20090104257A1 (en) * 2007-10-23 2009-04-23 Xingong Li Liposomal Vancomycin Formulations
WO2014085526A1 (en) * 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
US20150314002A1 (en) * 2012-11-29 2015-11-05 Insmed Incorporated Stabilized vancomycin formulations

Also Published As

Publication number Publication date
JP2020520986A (ja) 2020-07-16
CN110891590A (zh) 2020-03-17
US20200155640A1 (en) 2020-05-21
GB2577419A (en) 2020-03-25
US11857597B2 (en) 2024-01-02
IL270685A (https=) 2019-12-31
US11071769B2 (en) 2021-07-27
WO2018217808A1 (en) 2018-11-29
IL270686A (https=) 2019-12-31
US20220133843A1 (en) 2022-05-05
NZ758836A (en) 2025-11-28
US20200368312A1 (en) 2020-11-26
KR102661786B1 (ko) 2024-04-26
JP7210476B2 (ja) 2023-01-23
CN110891590B (zh) 2023-07-18
IL270686B (en) 2022-09-01
CN110996984A (zh) 2020-04-10
EP3634464A1 (en) 2020-04-15
BR112019024472A2 (pt) 2020-06-16
KR20200027922A (ko) 2020-03-13
NZ758839A (en) 2025-08-29
AU2018271873A1 (en) 2019-11-28
CA3062570A1 (en) 2018-11-29
WO2018217800A1 (en) 2018-11-29
AU2018273887B2 (en) 2022-09-08
GB201917677D0 (en) 2020-01-15
KR20200026803A (ko) 2020-03-11
JP7165146B2 (ja) 2022-11-02
AU2018273887A1 (en) 2019-11-28
CA3062567A1 (en) 2018-11-29
GB201917675D0 (en) 2020-01-15
KR102661790B1 (ko) 2024-04-26
EP3630154A1 (en) 2020-04-08
EP3630154A4 (en) 2021-03-10
JP2020520987A (ja) 2020-07-16
EP3634464A4 (en) 2021-04-07
GB2577420A (en) 2020-03-25
GB2577419B (en) 2022-08-17
IL270685B (en) 2022-09-01
BR112019024549A2 (pt) 2020-06-09
AU2018271873B2 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
IL273236A (en) Pyrazolopyrimidine compounds and their uses
IL268915A (en) Polymorphic compounds and their uses
IL277502A (en) Compounds and uses for them
GB201708652D0 (en) Novel compounds and uses
IL273493A (en) Modified CAR-T
GB201714745D0 (en) New compounds and uses
IL272808B (en) Pyridineamine-pyridone and pyrimidineamine-pyridone compounds
GB201714734D0 (en) New compounds and uses
GB2577420B (en) Glycopeptide derivative compounds and uses thereof
GB201714740D0 (en) New compounds and uses
IL279483A (en) Cyanotriazole compounds and their uses
IL292482B1 (en) Azaindolylpyridone and diazaindolylpyridone compounds
GB201714736D0 (en) New compounds and uses
GB201718324D0 (en) Zenaura 1
GB201712110D0 (en) New compounds and uses
GB201700404D0 (en) Compounds and composistions
HUE062120T2 (hu) Peptid-származék és alkalmazása
HK40027173A (en) Glycopeptide derivative compounds and uses thereof
GB201720092D0 (en) New Compounds and uses
GB201719327D0 (en) New compounds and uses
GB201719233D0 (en) New compounds and uses
GB201714743D0 (en) New compounds and uses
GB201717162D0 (en) Lightpack 2
GB201717202D0 (en) 11
AU2017293V (en) HANSOTI 13 Zamioculcas zamiifolia